<DOC>
	<DOC>NCT02536417</DOC>
	<brief_summary>The purpose of this study is to determine if melatonin administration to end-of-life patients is effective in preventing the development of delirium compared with those who do not receive this treatment. Delirium is a difficult to control symptom commonly seen in patients at the end-of-life. A person who is delirious is unable to think clearly and cannot make sense of what is going on around him/her.</brief_summary>
	<brief_title>Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients</brief_title>
	<detailed_description />
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Patients admitted to the test site Adult patients over 19 years of age Patients who can provide informed consent Patients who are able to tolerate oral medications Patients with existing delirium or dementia on admission Patients with poor clinical performance Patients taking melatonin prior to admission Patients taking medications that interact with melatonin Patients who are unable to provide informed consent Patients who are enrolled in any other research study involving drugs/devices</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Melatonin</keyword>
	<keyword>Delirium prevention</keyword>
	<keyword>End-of-life</keyword>
</DOC>